Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and Emactuzumab in R/R Follicular Lymphoma
NCT03369964Phase 1Withdrawn
- Sponsor
- Roche
- Start
- Mar 2018
- Primary completion
- Dec 2018
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of emactuzumab in follicular lymphoma (FL) (2 arms), sponsored by Roche. Primary endpoint: Percentage of Participants with Adverse Events. Planned start Mar 2018; status: withdrawn.
02
Drugs
emactuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03369964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03369964.